Resources
21 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 7/25/2022 (updated 3/27/2024)
The interactive graphics allow readers to explore how the crisis of overdose deaths involving opioid use has not only grown in magnitude since 2000, but has also changed in character.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 6/3/2022 (updated 3/27/2024)
During this session, Dr. Lopata discussed federal/HRSA investments focused on improving the health outcomes for and reducing health disparities among maternal and child health populations. More specifically, Dr. Lopata discussed the multiple programs/interventions funded by HRSA that together work (along with federal, state, regional, and local partners) to improve the prevention, screening, and treatment of opioid use disorder during pregnancy and Neonatal Abstinence Syndrome in the United States.
Posted 4/11/2023 (updated 3/27/2024)
The American Medical Association (AMA) Collective Trauma Toolkit includes 6 practical tools, actionable steps, and supporting resources to help your organization respond effectively to collective trauma.
Posted 11/1/2022 (updated 3/27/2024)
Last year, the National Association of County and City Health Officials (NACCHO) launched a resource meant to help local health departments (LHD) prevent or mitigate potentially traumatic events, known as adverse childhood experiences (ACEs). The Suicide, Overdose, and Adverse Childhood Experiences Prevention Capacity Assessment Tool (SPACECAT) allows LHDs to make an internal assessment of their capacity to address and prevent a still-growing public health issue.
Posted 4/11/2023 (updated 3/27/2024)
This webinar will help set a foundation for what trauma-informed care (TIC) means and why it is important.
Posted 10/23/2023 (updated 3/27/2024)
The 2023 RCORP-CABH Onboarding Packet includes resources, tools, and strategies to support grant-funded activities, along with information on accessing TA. We hope you find the Onboarding Packet helpful as a starting point. Our TA team is here to support you through your grant, so should you have any questions related to this document or other technical assistance needs, please do not hesitate to contact your Technical Expert Lead (TEL).
Posted 6/13/2023 (updated 3/28/2024)
Tribal communities throughout the United States are often acknowledged as having higher rates of negative health outcomes, including higher rates of overdose and substance use, with little context given to the contributing historical and contemporary factors.